N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(3-(morpholin-4-yl)phenyl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide | 499153-82-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(3-(morpholin-4-yl)phenyl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide
• 英文别名: 3-(4-((1H-pyrazol-1-yl)methyl)-2-(3-morpholinophenethoxy)phenyl)-N-(3,4-difluorophenylsulfonyl)propanamide；N-(3,4-difluorophenyl)sulfonyl-3-[2-[2-(3-morpholin-4-ylphenyl)ethoxy]-4-(pyrazol-1-ylmethyl)phenyl]propanamide
• CAS: 499153-82-1
• 化学式: C₃₁H₃₂F₂N₄O₅S
• 分子量: 610.682
• InChiKey: VVWKJHLPHXOIBG-UHFFFAOYSA-N

物化性质

• 密度：
  1.34±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  43
• 可旋转键数：
  12
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  111
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  3-(2-(2-(3-(morpholin-4-yl)phenyl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanoic acid 、 3,4-二氟苯磺酰胺 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 N-(3,4-difluorophenylsulfonyl)-3-(2-(2-(3-(morpholin-4-yl)phenyl)ethoxy)-4-(pyrazol-1-ylmethyl)phenyl)propanamide
  参考文献：
  名称：

  Discovery of novel N-acylsulfonamide analogs as potent and selective EP3 receptor antagonists

  摘要：

  A series of novel N-acylsulfonamide analogs were synthesized and evaluated for their binding affinity and antagonist activity for the EP3 receptor subtype. Representative compounds were also evaluated for their inhibitory effect on PGE(2)-induced uterine contraction in pregnant rats. Among those tested, a series of N-acylbenzenesulfonamide analogs were found to be more potent than the corresponding carboxylic acid analogs in both the in vitro and in vivo evaluations. The structure activity relationships (SAR) are also discussed. (C) 2010 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2010.02.034

文献信息

• CARBOXYLIC ACID DERIVATIVES AND PHARMACEUTICAL AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT
  申请人：Tani Kousuke

  公开号：US20090318703A1

  公开（公告）日：2009-12-24

  A carboxylic acid derivative of formula (I): wherein R 1 is —COOH, —COOR 6 , etc.; A is a single bond, alkylene, etc.; R 2 is alkyl, alkoxy, etc.; B is a carbocyclic ring or a heterocyclic ring; Q is alkylnene-Cyc2, etc.; D is a linking chain; and R 3 is alkyl, a carbocyclic ring or a heterocyclic ring, or a non-toxic salt thereof. The compound of formula (I) binds to PGE 2 receptor, especially subtypes EP 3 and/or EP 4 and show the antagonizing activity, are useful for the prevention and/or treatment of diseases induced pain, itch, urticaria, allergy, urinary frequency, urinary disturbance, Alzheimer's disease, cancer, dysmenorrhea, endometriosis, etc.

  化学式为（I）的羧酸衍生物：其中R1为—COOH，—COOR6等；A为单键，烷基等；R2为烷基，烷氧基等；B为碳环或杂环；Q为烷基烯-Cyc2等；D为连接链；R3为烷基，碳环或杂环，或其无毒盐。化合物（I）与PGE2受体结合，特别是亚型EP3和/或EP4，并显示拮抗活性，对于预防和/或治疗由疼痛、瘙痒、荨麻疹、过敏、尿频、尿液障碍、阿尔茨海默病、癌症、痛经、子宫内膜异位症等引起的疾病有用。
• Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
  申请人：Tani Kousuke

  公开号：US20060258728A1

  公开（公告）日：2006-11-16

  A carboxylic acid derivative of formula (I): wherein R 1 is —COOH, —COOR 6 , etc.; A is a single bond, alkylene, etc.; R 2 is alkyl, alkoxy, etc.; B is a carbocyclic ring or a heterocyclic ring; Q is alkylnene-Cyc2, etc.; D is a linking chain; and R 3 is alkyl, a carbocyclic ring or a heterocyclic ring, or a non-toxic salt thereof. The compound of formula (I) binds to PGE 2 receptor, especially subtypes EP 3 and/or EP 4 and show the antagonizing activity, are useful for the prevention and/or treatment of diseases induced pain, itch, urticaria, allergy, urinary frequency, urinary disturbance, Alzheimer's disease, cancer, dysmenorrhea, endometriosis, etc.

  化学式为（I）的羧酸衍生物：其中R1为—COOH，—COOR6等；A为单键，烷基等；R2为烷基，烷氧基等；B为碳环或杂环；Q为烷基烯-Cyc2等；D为连接链；R3为烷基，碳环或杂环，或其无毒盐。化合物（I）与PGE2受体结合，特别是亚型EP3和/或EP4，并显示拮抗活性，可用于预防和/或治疗因疼痛、瘙痒、荨麻疹、过敏、尿频、尿障碍、阿尔茨海默病、癌症、痛经、子宫内膜异位症等引起的疾病。
• CARBOXYLIC ACID DERIVATIVE COMPOUNDS AND DRUGS COMPRISING THESE COMPOUNDS AS THE ACTIVE INGREDIENT
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1431267A1

  公开（公告）日：2004-06-23

  A carboxylic acid derivative of formula (I): wherein R1 is -COOH, -COOR6, etc.; A is a single bond, alkylene, etc.; R2 is alkyl, alkoxy, etc.; B is a carbocyclic ring or a heterocyclic ring; Q is alkylnene-Cyc2, etc.; D is a linking chain; and R3 is alkyl, a carbocyclic ring or a heterocyclic ring, or a non-toxic salt thereof. The compound of formula (I) binds to PGE2 receptor, especially subtypes EP3 and/or EP4 and show the antagonizing activity, are useful for the prevention and/or treatment of diseases induced pain, itch, urticaria, allergy, urinary frequency, urinary disturbance, Alzheimer's disease, cancer, dysmenorrhea, endometriosis, etc.

  式(I)的羧酸衍生物： 其中 R1 为-COOH、-COOR6 等；A 为单键、亚烷基等；R2 为烷基、烷氧基等；B 为碳环或杂环；Q 为烷基烯-Cyc2 等；D 为连接链；R3 为烷基、碳环或杂环，或其无毒盐。式（I）化合物能与 PGE2 受体，特别是 EP3 和/或 EP4 亚型结合并显示出拮抗活性，可用于预防和/或治疗诱发疼痛、瘙痒、荨麻疹、过敏、尿频、排尿障碍、老年痴呆症、癌症、痛经、子宫内膜异位症等疾病。
• US7491748B2
  申请人：——

  公开号：US7491748B2

  公开（公告）日：2009-02-17
• US7786161B2
  申请人：——

  公开号：US7786161B2

  公开（公告）日：2010-08-31